Submitted by Anonymous (not verified) on 7 July 2025 - 11:24
Opinion/decision on a Paediatric investigation plan (PIP): Fasenra, Benralizumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Blood and lymphatic system disorders, PIP number: P/0307/2024
Source: